Sreenija Suryadevara, MD
Endocrinology, Diabetes & Metabolism · Lebanon, NHNPI 1073832564
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 290 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 41 manufacturers, the largest accounting for just 14.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,188 and has fallen 82.8% since, to $205 in 2025.
Across 290 payments — averaging $15.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$630
- Amgen$355
- Abbott$315
- Sanofi-aventis U.S. LLC$263
- Radius Health, Inc.$228
- Xeris Pharmaceuticals, Inc.$203
- plus $2K from 35 others
What the payments were for
- Food & beverage$4,35399%
- Education$431%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 55 | $630 |
| Amgen(2 entities) | 23 | $355 |
| Abbott | 20 | $315 |
| Sanofi-aventis U.S. LLC | 16 | $263 |
| Radius Health, Inc. | 18 | $228 |
| Xeris Pharmaceuticals, Inc. | 11 | $203 |
| AbbVie | 13 | $196 |
| Dexcom, Inc. | 14 | $190 |
| Aimmune Therapeutics, Inc. | 13 | $169 |
| Corcept Therapeutics | 10 | $169 |
| Amneal Pharmaceuticals LLC | 9 | $145 |
| Mannkind Corporation | 9 | $141 |
| AstraZeneca | 8 | $123 |
| Medtronic(2 entities) | 6 | $117 |
| Amarin Pharma, Inc. | 8 | $114 |
| Sequel Med Tech, LLC | 1 | $105 |
| Lilly USA, LLC | 6 | $96 |
| Nestle Healthcare Nutrition Inc. | 5 | $90 |
| Antares Pharma, Inc. | 4 | $63 |
| Esperion Therapeutics, Inc. | 4 | $62 |
| Novartis | 4 | $55 |
| Tandem Diabetes Care, Inc. | 3 | $53 |
| Nevro Corp. | 3 | $53 |
| GSK | 2 | $46 |
| Zealand Pharma US, Inc. | 2 | $42 |
| Kowa Pharmaceuticals America, Inc. | 2 | $41 |
| Johnson & Johnson | 3 | $40 |
| Bayer | 2 | $38 |
| Shire North American Group Inc | 2 | $35 |
| IBSA Pharma Inc. | 2 | $31 |
| Ascensia Diabetes Care US Inc. | 2 | $31 |
| Recordati_rare_diseases_inc. | 1 | $20 |
| Insulet Corporation | 1 | $20 |
| Clarus Therapeutics Inc. | 1 | $18 |
| Pfizer | 1 | $17 |
| Aegerion Pharmaceuticals, Inc. | 1 | $17 |
| BD | 1 | $16 |
| Amryt Pharma Holdings Ltd | 1 | $14 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
| Merck | 1 | $12 |
| Boehringer Ingelheim | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TWIIST$105
How this compares
$4,397 in reported general payments places this provider in the 85th percentile of 37 endocrinology, diabetes & metabolism providers in New Hampshire.
See all endocrinology, diabetes & metabolism providers in New Hampshire →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 509 | $835,656 |
| MounjaroTirzepatide | 225 | $375,616 |
| JardianceEmpagliflozin | 212 | $278,547 |
| TrulicityDulaglutide | 129 | $201,830 |
| FarxigaDapagliflozin Propanediol | 124 | $153,846 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 88 | $96,652 |
| ForteoTeriparatide | 20 | $79,527 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 76 | $72,032 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 36 | $65,295 |
| Tresiba Flextouch U-200Insulin Degludec | 38 | $60,177 |
| Tresiba Flextouch U-100Insulin Degludec | 47 | $47,251 |
| RybelsusSemaglutide | 22 | $43,549 |
| Humalog Kwikpen U-200Insulin Lispro | 23 | $42,815 |
| JanuviaSitagliptin Phosphate | 26 | $33,772 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $30,079 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $630 | $890,089569 claims |
| Lilly USA, LLCMounjaro, Trulicity, Forteo, Humalog, Insulin Lispro | $96 | $680,884475 claims |
| Boehringer IngelheimJardiance, Synjardy | $11 | $284,770224 claims |
| AstraZenecaFarxiga | $123 | $153,846124 claims |
| MerckJanuvia | $12 | $33,77226 claims |
| AbbVieSynthroid | $196 | $27,102234 claims |
| Johnson & JohnsonInvokana | $40 | $14,30313 claims |
| IBSA Pharma Inc.Tirosint | $31 | $7,02031 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $145 | $5,944656 claims |
| Sanofi-aventis U.S. LLCLantus | $263 | $2,81114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 37 endocrinology, diabetes & metabolism providers in New Hampshire.
Other endocrinology, diabetes & metabolism in Lebanon
- Harpreet RaiLebanon$2K
- Sushmitha EchtLebanon$233
- Murray KorcLebanon$155
- Paul BeisswengerLebanon$110
- Eric EpsteinLebanon$85
- Ugis GruntmanisLebanon$61
- Richard ComiLebanon$40
- Sushela ChaidarunLebanon$0
- Michael DavidsonDover$204K
- Matthew KamilConcord$163K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.